Etaracizumab

Etaracizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	alpha-v beta-3 integrin
Clinical data
Trade names	Abegrin
ATC code	none
Identifiers
CAS Number	892553-42-3^N
ChemSpider	none
UNII	41W9MFI160^Y
KEGG	D09342^Y
Chemical and physical data
Formula	C₆₃₉₂H₉₉₀₈N₁₇₃₂O₁₉₉₆S₄₂
Molar mass	144.3 kg/mol
^NY (what is this?) (verify)

Etaracizumab (also known as etaratuzumab, MEDI-522, trade name Abegrin) is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer,^[1] ovarian cancer^[2] and various other types of cancer.^[3] It is manufactured by MedImmune.^[1]

References

1 2 Statement On A Nonproprietary Name Adopted By The Usan Council: Etaracizumab
↑ Landen, CN; Kim, TJ; Lin, YG; Merritt, WM; Kamat, AA; Han, LY; Spannuth, WA; Nick, AM; Jennnings, NB (2008). "Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer". Neoplasia. 10 (11): 1259–67. PMC 2570602. PMID 18953435.
↑ Delbaldo, C; Raymond, E; Vera, K; Hammershaimb, L; Kaucic, K; Lozahic, S; Marty, M; Faivre, S (2008). "Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors". Investigational new drugs. 26 (1): 35–43. doi:10.1007/s10637-007-9077-0. PMID 17876527.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-osu-")	Burosumab Denosumab

Humanized ("-sozu-")	Blosozumab Romosozumab

Musculoskeletal ("-mul-")

Human ("-mulu-")	Stamulumab^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab Vesencumab

Mouse ("-ciro-")	Biciromab^‡ Imciromab^‡

Chimeric ("-cixi-")	Abciximab Volociximab

Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Etaracizumab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab Atinumab Erenumab Fasinumab Fulranumab Gantenerumab Opicinumab

Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab^† Crenezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab

Angiogenesis inhibitor ("-anibi-")

Humanized ("-anibizu-")	Ranibizumab

Growth factor ("-gr(o)-")

Human ("-gru-")	Bimagrumab

Humanized ("-grozu-")	Domagrozumab Landogrozumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Seribantumab Tarextumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma) Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Derlotuximab biotin Dinutuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Abituzumab Alemtuzumab Bevacizumab Bivatuzumab mertansine Brontictuzumab Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Denintuzumab mafodotin Elotuzumab Emactuzumab Emibetuzumab Enoblituzumab Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Lumretuzumab Matuzumab^§ Milatuzumab Nimotuzumab Obinutuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Vandortuzumab vedotin Veltuzumab Vorsetuzumab mafodotin "-gozu-" (ovarian tumor) Sofituzumab vedotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin Ontuxizumab

Veterinary ("-tuvet-")	Blontuvetmab Tamtuvetmab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 9/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.